Detailed Narrative
FY26 Financial Performance and Strategic Milestones
Stallion India Fluorochemicals Ltd. reported a strong financial year for FY26, with total revenue reaching ₹434.12 crores, marking a 14.4% year-on-year growth. EBITDA increased by 23.34% to ₹61.35 crores, and PAT grew by an impressive 35.61% to ₹43.84 crores, surpassing the company's internal targets of ₹430 crores revenue and ₹40 crores PAT. A significant strategic achievement was receiving environmental clearance for the proposed 10,000 metric ton R-32 manufacturing facility at Bhilwara, Rajasthan, with production expected to commence by October 2026.
Project Expansion and Timelines
The company is actively expanding its manufacturing footprint with several projects nearing completion. The Khalapur helium plant is in its final testing phase and is expected to be operational by next month (June 2026). The Mumbattu facility in Andhra Pradesh, which has been expanded 2.5 times from its initial IPO project scope to a 12-tank facility, is slated to be operational by August 2026. This facility will enhance the company's presence in South India and add capabilities for HFO/HFC refrigerant blending, de-bulking, helium, and semiconductor gas handling.
Capex Strategy and Funding
For the Bhilwara R-32 facility, the total planned capex is around ₹200 crores, with ₹35 crores spent so far. Management clarified that the low current spend is due to a conservative payment policy, where significant payments are made upon delivery and commissioning rather than upfront. The total capex for the HFO plant is estimated to be around ₹400 crores. The company maintains a healthy cash balance of ₹434 crores and has ₹120 crores in undrawn OD/CC facilities, indicating sufficient liquidity for planned capex without further dilution.
Growth Outlook and Margin Projections
Stallion India projects a revenue growth CAGR of 30-35% over the next three years, coupled with margin improvements of 3-4%. For FY27, with six months of R-32 production, the company anticipates an additional ₹250 crores in revenue, contributing to a total PAT of approximately ₹100-110 crores. The long-term vision includes achieving ₹3,000 crores in revenue and ₹500 crores in PAT by 2030. PAT margins are expected to remain consistent in H1 FY27 but climb by 5-6% in H2 FY27 due to contributions from new manufacturing facilities.
Market Dynamics and R-32 Strategy
The company acknowledges current geopolitical uncertainties and supply chain disruptions, which led to a Q4 FY26 revenue de-growth to ₹110 crores from ₹120 crores in Q4 FY25, primarily due to end-customer production issues. Despite this, management is confident in the R-32 market, expecting to secure a 10,000-ton quota. They have opted not to enter pre-contracts for R-32, believing it to be detrimental, and see significant export potential for R-32 and HFO blends, contributing to India becoming a net exporter in fluorochemicals.
Semiconductor and High Purity Gases Opportunity
Stallion India is positioning itself to capitalize on emerging opportunities in the electronics, semiconductors, and healthcare sectors through its specialty gas expansion. The company views India's nascent but rapidly evolving semiconductor industry as a major growth driver. They emphasize that building presence in this sector requires patience and resilience, with initial commercial contributions expected once the helium facility starts up in June, serving as an entry point for broader sales.